{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:25Z","timestamp":1785240385305,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:55:14Z","timestamp":1776610514000},"page":"e876-e884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0730-1355","authenticated-orcid":false,"given":"Paolo","family":"Fiore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Calimeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.clml.2026.04.008_bib0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0002","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind\u2014changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0004","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0006","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"Primary central nervous system lymphomas: EHA\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Ferreri","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0007","first-page":"477","article-title":"Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data","volume":"30","author":"Dandachi","year":"2019","journal-title":"Cancer Causes Control"},{"issue":"8","key":"10.1016\/j.clml.2026.04.008_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/cncr.22989","article-title":"Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey","volume":"110","author":"Haldorsen","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.04.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211066166","article-title":"Primary central nervous system lymphoma in the United States, 1975\u20132017","volume":"13","author":"Lv","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clml.2026.04.008_bib0011","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/leu.2017.128","article-title":"Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015","volume":"31","author":"van der Meulen","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/cancers13030403","article-title":"Changing incidence and survival of primary Central nervous system lymphoma in Australia: a 33-year national population-based study","volume":"13","author":"Farrall","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0013","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00415-015-7713-8","article-title":"Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study","volume":"262","author":"Matinella","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.clml.2026.04.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025031869","article-title":"Immunodeficiency-associated primary CNS lymphomas: an International primary CNS lymphoma Collaborative Group (IPCG) Study","author":"Kaulen","year":"2026","journal-title":"Blood J"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0016","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-020-03525-5","article-title":"Use of FDG-PET\/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study","volume":"148","author":"Bertaux","year":"2020","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0018","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00104-2","article-title":"Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10","volume":"11","author":"Calimeri","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/s41375-025-02583-w","article-title":"Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid","volume":"39","author":"Weinschenk","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.04.008_bib0021","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.04.008_bib0023","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12348-023-00342-5","article-title":"Challenges in posterior uveitis\u2014Tips and tricks for the retina specialist","volume":"13","author":"Paez-Escamilla","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International extranodal lymphoma study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clml.2026.04.008_bib0026","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary Central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0027","first-page":"38","article-title":"Brain tumor segmentation and identification using particle imperialist deep convolutional neural network in MRI images","volume":"7","author":"Amit Khemchandani","year":"2022","journal-title":"Int J Interact Multimedia Artif Intell"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0028","first-page":"35","article-title":"Promising deep semantic nuclei segmentation models for multi-institutional histopathology images of different organs","volume":"6","author":"Hassan","year":"2021","journal-title":"Int J Interact Multimedia Artif Intell"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0029","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1148\/radiol.2021202553","article-title":"The biological meaning of radiomic features","volume":"298","author":"Tomaszewski","year":"2021","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0030","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.30309","article-title":"The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0031","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41747-018-0068-z","article-title":"Radiomics: the facts and the challenges of image analysis","volume":"2","author":"Rizzo","year":"2018","journal-title":"Eur Radiol Exp"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0032","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0033","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3174\/ajnr.A5391","article-title":"Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches","volume":"39","author":"Zhou","year":"2018","journal-title":"American Journal of Neuroradiology"},{"issue":"9","key":"10.1016\/j.clml.2026.04.008_bib0034","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/neuonc\/noy021","article-title":"Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation","volume":"20","author":"Kang","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2026.04.008_bib0035","article-title":"Comparison of radiomics-based machine-learning classifiers in diagnosis of glioblastoma from primary Central nervous system lymphoma","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0036","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jmri.27344","article-title":"<scp>multiparametric-MRI<\/scp>-based radiomics model for differentiating primary Central nervous system lymphoma from glioblastoma: development and cross-vendor validation","volume":"53","author":"Xia","year":"2021","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0037","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1038\/s41598-019-42276-w","article-title":"Radiomic features and multilayer perceptron network classifier: a robust MRI classification strategy for distinguishing glioblastoma from primary central nervous system lymphoma","volume":"9","author":"Yun","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clml.2026.04.008_bib0038","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/brainsci10110886","article-title":"Classification of primary cerebral lymphoma and glioblastoma featuring dynamic susceptibility contrast and apparent diffusion coefficient","volume":"10","author":"Eisenhut","year":"2020","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0039","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2463\/mrms.mp.2017-0044","article-title":"Comparison between glioblastoma and primary Central nervous system lymphoma using MR image-based texture analysis","volume":"17","author":"Kunimatsu","year":"2018","journal-title":"Magn Reson Med Sci"},{"issue":"12","key":"10.1016\/j.clml.2026.04.008_bib0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00234-018-2091-4","article-title":"Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI","volume":"60","author":"Kim","year":"2018","journal-title":"Neuroradiology"},{"issue":"11","key":"10.1016\/j.clml.2026.04.008_bib0041","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1007\/s00330-020-06927-1","article-title":"Current status and quality of radiomics studies in lymphoma: a systematic review","volume":"30","author":"Wang","year":"2020","journal-title":"Eur Radiol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0042","first-page":"29","article-title":"A radiomic machine learning model to predict treatment response to methotrexate and survival outcomes in primary Central nervous system lymphoma (PCNSL)","volume":"136","author":"Ali","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/bioengineering10030285","article-title":"Radiomics-based machine learning model for predicting overall and progression-free survival in rare cancer: a case study for primary CNS lymphoma patients","volume":"10","author":"Destito","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.clml.2026.04.008_bib0044","doi-asserted-by":"crossref","unstructured":"Chen C., Zhuo H., Wei X., Ma X. Contrast-enhanced MRI texture parameters as potential prognostic factors for primary central nervous system lymphoma patients receiving high-dose methotrexate-based chemotherapy. 2019. Available at: http:\/\/www.lifexsoft.org.","DOI":"10.1155\/2019\/5481491"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11060-023-04554-6","article-title":"Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma","volume":"166","author":"Wang","year":"2024","journal-title":"J Neurooncol"},{"issue":"17","key":"10.1016\/j.clml.2026.04.008_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70182","article-title":"Radiomic prediction for durable response to high-dose methotrexate-based chemotherapy in primary central nervous system lymphoma","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0047","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/jmri.29533","article-title":"Prognostic assessment in patients with primary diffuse large B-cell lymphoma of the Central nervous system using MRI-based radiomics","volume":"61","author":"Liu","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.clml.2026.04.008_bib0048","doi-asserted-by":"crossref","unstructured":"Ko C.C., Liu Y.L., Hung K.C., et al. MRI-based machine learning for prediction of clinical outcomes in primary Central nervous system lymphoma. 2024;14(10):1290. Available at: 10.3390\/life14101290.","DOI":"10.3390\/life14101290"},{"key":"10.1016\/j.clml.2026.04.008_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112125","article-title":"Prediction of early recurrence in primary central nervous system lymphoma based on multimodal MRI-based radiomics: a preliminary study","volume":"188","author":"Wang","year":"2025","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0050","article-title":"Radiomic features define risk and are linked to DNA methylation attributes in primary CNS lymphoma","volume":"5","author":"Nenning","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"10","key":"10.1016\/j.clml.2026.04.008_bib0051","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s11548-023-02886-2","article-title":"Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma","volume":"18","author":"She","year":"2023","journal-title":"Int J Comput Assist Radiol Surg"},{"issue":"4","key":"10.1016\/j.clml.2026.04.008_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100213","article-title":"How we treat primary central nervous system lymphoma","volume":"6","author":"Calimeri","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0054","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.008_bib0055","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.clml.2026.04.008_bib0056","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2026.04.008_bib0057","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","article-title":"Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)","volume":"38","author":"Omuro","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2026.04.008_bib0058","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0059","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16592","article-title":"Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival","volume":"190","author":"Martinez-Calle","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.008_bib0060","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00371-X","article-title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial","volume":"11","author":"Schorb","year":"2024","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.clml.2026.04.008_bib0062","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.04.008_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0064","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes associated with thiotepa-based conditioning in patients with primary Central nervous system lymphoma after autologous hematopoietic cell transplant","volume":"7","author":"Scordo","year":"2021","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.04.008_bib0065","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2026.04.008_bib0066","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy As first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.04.008_bib0067","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0068","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-019-5473-z","article-title":"Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients","volume":"19","author":"Schorb","year":"2019","journal-title":"BMC Cancer"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2026.04.008_bib0069","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171733","volume":"140","author":"Illerhaus","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.04.008_bib0070","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.04.008_bib0071","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0072","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjh.15787","article-title":"Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma","volume":"186","author":"Vu","year":"2019","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0073","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2025-900","article-title":"Low-dose lenalidomide for maintenance of remission in primary central nervous system lymphoma: a single-center experience","volume":"146","author":"Randall","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.ijrobp.2006.03.061","article-title":"Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: results of North Central Cancer Treatment Group (NCCTG) 96-73-51","volume":"65","author":"Laack","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0076","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cns.15.34","article-title":"Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy","volume":"4","author":"Ambady","year":"2015","journal-title":"CNS Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0077","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation As salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0078","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2037","article-title":"Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy","volume":"31","author":"Mappa","year":"2013","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.04.008_bib0079","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.04.008_bib0080","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.V126.23.1524.1524","article-title":"Very high efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in relapse\/refractory (R\/R) primary Central nervous system (PCNSL) and vitreo-retinal (VRL) Non hodgkin lymphoma. A LOC network multicenter retrospective study on 58 cases","volume":"126","author":"Choquet","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2026.04.008_bib0081","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/bloodadvances.2021004779","article-title":"A phase 1\/2 study of thiotepa-based immunochemotherapy in relapsed\/refractory primary CNS lymphoma: the TIER trial","volume":"5","author":"Fox","year":"2021","journal-title":"Blood Adv"},{"issue":"S3","key":"10.1016\/j.clml.2026.04.008_bib0082","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_86","article-title":"86 | Efficacy of thiotepa-conditioned autologous transplantation is independent of response to Hd-mtx-based induction in primary Cns Lymphoma: EBMT series of 1545 patients","volume":"43","author":"Calimeri","year":"2025","journal-title":"Hematol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2026.04.008_bib0083","first-page":"7515","article-title":"Updated results of single-agent ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"35","author":"Grommes","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.008_bib0084","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.04.008_bib0085","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0086","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2024-199168","article-title":"Phase 1 study of escalating doses of Ibrutinib in Teddi-R with Isavuconazole for relapsed and refractory primary DLBCL of the CNS","volume":"144","author":"Roschewski","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.008_bib0087","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2026.04.008_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary evaluation of Zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of Zanubrutinib: a 13-case series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.008_bib0089","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary Central nervous system lymphoma: a retrospective analysis of case series","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.008_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.HS9.0000843788.10370.07","article-title":"S224: preliminary results of a phase ii study of orelabrutinib in combination with anti-PD-1 monoclonal antibody in refractory or relapsed primary cns lymphoma","volume":"6","author":"Zhang","year":"2022","journal-title":"Hemasphere"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.04.008_bib0091","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2025.43.16_suppl.2019","article-title":"Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: efficacy and safety from the phase II PROSPECT study","volume":"43","author":"Nayak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.008_bib0092","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.clml.2026.04.008_bib0093","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.04.008_bib0094","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.clml.2026.04.008_bib0095","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0096","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1182\/blood-2023-186087","article-title":"Preliminary results from a phase I\/II study of pomalidomide plus Rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory diffuse large B-cell lymphoma (PRIDE)","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.04.008_bib0097","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.0000000000012515","article-title":"Rituximab-lenalidomide-ibrutinib combination for relapsed\/refractory primary CNS lymphoma","volume":"97","author":"Houillier","year":"2021","journal-title":"Neurology"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0098","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2022-157001","article-title":"Phase ib\/II trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, Ibrutinib, in combination with rituximab and lenalidomide in refractory\/recurrent primary (PCNSL) and secondary Central nervous system lymphoma (SCNSL)","volume":"140","author":"Grommes","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0099","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1182\/blood-2023-186488","article-title":"Rituximab Ibrutinib lenalidomide (R2I) combination for primary or secondary large B-cell CNS lymphoma: last resort or bridge to cellular therapy?","volume":"142","author":"Perez Perez","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.04.008_bib0100","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/neuonc\/noaf104","article-title":"Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed\/refractory central nervous system lymphoma","volume":"27","author":"Schaff","year":"2025","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.04.008_bib0101","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.04.008_bib0102","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/10428194.2018.1480771","article-title":"Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma","volume":"60","author":"Ambady","year":"2019","journal-title":"Leuk Lymph"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.008_bib0103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141773","article-title":"First results of the Acs\u00e9 Pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort","volume":"136","author":"Hoang-Xuan","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0104","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/bloodadvances.2024014635","article-title":"Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas","volume":"9","author":"Chihara","year":"2025","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.clml.2026.04.008_bib0105","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.clml.2026.04.008_bib0106","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.04.008_bib0107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.008_bib0108","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.04.008_bib0109","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285613","article-title":"Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy","author":"Mercadal","year":"2024","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:55:19Z","timestamp":1785239719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001084"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}